

Brussels, BELGIUM – August 1st, 2014 – Nipro Europe (Head Office: Brussels, Belgium) announced today the completion of the acquisition of a majority stake of 51% in Rigi Medizintechnik GmbH (Head Office: Freienbach, Switzerland).

This latest acquisition is part of Nipro Europe's strategy to vertically integrate its supply chain from manufacturing to the patient. That strategy included the expansion of its product portfolio through the additions of manufacturers Nipro Renal Solutions (Nov 2013) and Nipro Pure Water (Jan 2014) and is now continued through the addition of 7 direct sales territories.

The acquisition announced today will indeed expand significantly Nipro Europe's territory with representations in 6 countries in Western Europe, Eastern Europe and CIS as well as South Africa. These include Germany and the UK, countries with a significant number of dialysis patients as well as growth markets such as Turkey and Kazakhstan.

Kurt van Dal, the current President and CEO of Nipro Europe, says; "We have had a very close relationship with Rigi Medizintechnik since it's foundation in 2010 and have seen this company grow to be a significant player in several of the most important markets in our territory. The acquisition of the majority stake of 51% brings Nipro Europe much closer to the 150.000 patients treated in these markets and allows us to react even quicker to the needs of our customers in terms of logistics and product development." says Mr. Van Dal.

The agreement has been signed August 1st and will be effective as of January 1st 2015. It will have no significant impact on the Nipro Group consolidated results.

About Nipro Corporation:

Nipro Corporation (Tokyo Stock Exchange and Osaka Stock Exchange Ticker Code 8086), founded in 1954, is engaged directly and through its subsidiaries principally in the development, manufacture and sale of medical devices, pharmaceutical products and medical and glass products. Nipro's medical device division is engaged in the manufacture and sale of medical devices and its related products, the development, manufacture and sale of cell culturing-related products, as well as the development and sale of diabetes-related products. Nipro's pharmaceutical division is engaged in the research, manufacture and sale of pharmaceuticals, such as blood derivatives. The instrument division of Nipro manufactures and sells glass pipes and other glass products, including the inner bottles of thermos bottles. Nipro and its subsidiaries also sell medical device manufacturing equipment and conduct real estate leasing and non-life insurance agency businesses. For more information, please visit www.nipro.co.jp

About Nipro Europe

Nipro Europe is a subsidiary of Nipro Corporation is engaged directly and through its subsidiaries principally in the sale of medical devices and pharmaceutical packaging glass products. Nipro's medical device division is engaged in the sale of Infusion products, devices and disposables for dialysis treatments including but not limited to dialysis devices, water treatment devices, dialyzers, bloodlines and venous access devices. It is also active in the sale of diabetes and cardiovascular related products. For more information please visit www.nipro-europe.com.